Molecular Abnormalities of mdm2 and p53 Genes in Adult Soft Tissue Sarcomas

Cancer Research

Volumn 54, Issue 3, 1994, Pages 794-799

  Cordon Cardo, Carlos ^a   Latres, Esther ^a   Drobnjak, Marya ^a   Oliva, Maria R ^a   Pollack, Daphna ^a   Woodruff, James M ^a   Marechal, Vincent ^b   Chen, Jiandong ^b   Brennan, Murray F ^a   Levine, Arnold J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEIN P53;

ADULT; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; POINT MUTATION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOFT TISSUE SARCOMA; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

ADULT; ANALYSIS OF VARIANCE; CELL NUCLEUS; COHORT STUDIES; DNA, NEOPLASM; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENES, P53; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0028098165     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Fields, S., and Jang, S. K. Presence of a potent transcription activating sequence in the p53 protein. Science (Washington DC), 249: 1046-1049, 1990.
2. Raycroft, L., Wu, H., and Lozano, G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (Washington DC), 249: 1049-1051, 1990.
3. Bargonetti, J., Friedman, P. N., Kern, S. E., Vogelstein, B., and Prives, C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 65: 1083-1091, 1991.
4. Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., and Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science (Washington DC), 252: 1708-1711, 1991.
5. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. Definition of a consensus binding site for P53. Nat. Genet., 1: 45-49, 1992.
6. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12: 2866-2871, 1992.
7. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev., 6: 1143-1152, 1992.
8. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. Wild-type p53 activates transcription w vitro. Nature (Lond.), 358: 83-86, 1992.
9. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827-830, 1992.
10. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA, 89: 12028-12032, 1992.
11. Hollstein, M. C., Metcalf, R. A., Welsh, J. A., Montesano, R., and Harris, C. C. Frequent mutation of thep. 5 gene in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 87: 9958-9961, 1990.
12. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 357: 453-456, 1991.
13. Donehower, I. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
14. Levine, A. J. The p53 tumor-suppressor gene. N. Engl. J. Med., 326: 1350-1352, 1992.
15. Martinez, J., Georgoff, I., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes & Dev., 5: 151-159, 1991.
16. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, J. A mammalian cell cycle checkpoint pathway utilizing p53 and Gadd45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
17. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
18. Tin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, C. C., and Wahl, E. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.
19. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-354, 1991.
20. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
21. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by a p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
22. Linzer, D. I. H., and Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen in SV40 transformed cells. Cell, 17: 43-52, 1979.
23. Lane, D. P., and Crawford, L. V. T-antigen is bound to host protein in SV40-transformed cells. Nature (Lond.), 278: 261-263, 1979.
24. Sarnow, R., Ho, Y. S., Williams, J., and Levine, A. J. Adenovirus ElB-58Kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 Kd cellular protein in transformed cells. Cell, 28: 387-394, 1982.
25. Werness, B. A., Levine, A. J., and Howley, R M. The E6 proteins encoded by human papillomavirus type 16 and 18 can complex p53 in vitro. Science (Washington DC), 248: 76-79, 1990.
26. Yew, P. R., and Berk, A. J. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature (Lond.), 357: 82-85, 1992.
27. Mietz, J. A., Unger, T., Huibregtse, J. M., and Howley, P. M. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 11: 5013-5020, 1992.
28. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. Tumorigcnic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10: 1565-1569, 1991.
29. Momand, J., Zambetti, G. P., Olson, D. C., George, D. L., and Levine, A. J. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
30. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
31. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. p53 mutation and mdml amplification in human soft tissue sarcomas. Cancer Res., 53: 2231-2234, 1993.
32. Ladanyi, M., Cha, C., Lewis, R., Jhanwar, S. C., Huvos, A. G., and Healey, J. H. mdml gene amplification in metastatic osteosarcoma. Cancer Res., 53: 16-18, 1993.
33. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm2 interaction domains. Mol. Cell. Biol., 13: 4107-4114, 1993.
34. Olson, D., Marechal, V., Momand, J., Chen, J., Romocki, C., and Levine, A. J. Identification and characterization of multiple mdm2 proteins and mdm2 p53 protein complexes. Oncogene, 8: 2353-2360, 1993.
35. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
36. Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
37. Ball, R. K., Quellhorst, S., Brandner, G., and Braun, D. G. Monoclonal antibodies against simian virus 40 nuclear large T tumor antigen: epitope mapping, papova virus cross-reaction and cell surface staining. EMBO J., 3: 1485-1491, 1984.
38. Presti, J. C., Reuter, V. E., Galan, T., Fair, W. R., and Cordon-Cardo, C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 51: 5405-5409, 1991.
39. Dalbagni, G., Presti, J. J. C., Reuter, V. E., Zhang, Z. R., Sarkis, A., Fair, W. R., and Cordon-Cardo, C. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn. Mol. Pathol., 2: 4-13, 1993.
40. Olumi, A. F., Tsai, Y. C., Nichols, P.w., Skinner, D. G., Cain, D. R., Bender, L. I., and Jones, P. A. Allelic loss of chromosomes 17p distinguishes high grade from low-grade transitional cell carcinomas of the bladder. Cancer Res., 50: 7081-7083, 1990.
41. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive deletion of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
42. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
43. Sanger, R., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
44. Mehta, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in r X c contingency tables. J. Am. Statist. Assoc., 78: 427-434, 1983.
45. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc., 53: 457-481, 1958.
46. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35: 1-39, 1977.
47. Cox, D. R. Partial likelihood. Biometrika, 62: 269-279, 1975.
48. Reich, N. C., Oren, M., and Levine, A. J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol., 3: 2143-2150, 1983.
49. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Nat. Cancer Inst., 84: 1109-1114, 1992.
50. Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-854, 1992.
51. Starzynska, T., Bromley, M., Ghosh, A., and Stern, B. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66: 558-562, 1992.
52. Remvikos, Y., Tominaga, O., Hammel, P., Laurent-Puig, P., Salmon, R. J., Dutrillaux, B., and Thomas, G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66: 758-764, 1992.
53. McLaren, R., Kuzu, I., Dunnill, M., Harris, A., Lane, D., and Garter, K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66: 735-738, 1992.
54. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
55. Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P., and Silvestre, F. p53 expression and prognosis in gastric carcinoma. Int. J. Cancer, 50: 859-862, 1992.
56. Jaros, E., Perry, R. H., Adam, L., Kelly, P. J., Crawford, P. J., Kalbag, R. M., Mendelow, A. D., Sengupta, R. P., and Pearson, A. D. J. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br. J. Cancer, 66: 373-385, 1992.
57. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
58. Wu, X., Bayle, H., Olson, D., and Levine, A. J. The p53-mdm2 autoregulatory feedback loop. Genes & Dev., 7: 1126-1132, 1993.
59. Dittmer, D., Sibani, P., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nature (Lond.), 4: 42-45, 1993.
60. Callahan, R. p53 mutations, another breast cancer prognostic factor. J. Natl. Cancer Inst., 84: 826-827, 1992.